Approval · Notice of Compliance 11268 · 2010
TEVA-GABAPENTIN: Notice of Compliance 11268
Issued April 20, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11268
- Date
- April 20, 2010
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- Antiepileptic agent
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-GABAPENTIN | 02244513 | Marketed |
| TEVA-GABAPENTIN | 02244514 | Marketed |
| TEVA-GABAPENTIN | 02244515 | Marketed |
| TEVA-GABAPENTIN | 02248457 | Marketed |
| TEVA-GABAPENTIN | 02247346 | Marketed |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP
- GABAPENTIN 600 MG per CAP
- GABAPENTIN 800 MG per CAP